top of page
Screen Shot 2023-04-27 at 3.01.31 PM.png

Travis Quigley

SVP and Head of Clinical Development

Travis brings over 20 years of oncology and drug development experience to K36 Therapeutics, Inc. Travis recently served as the Global Platform Leader for CAR-NK at Takeda. Prior to Takeda, he was the Vice President of Clinical Development and Program Leadership at Arcellx, Inc. a start-up developing controllable CAR-T cells for Multiple Myeloma. Prior to Arcellx, Travis was Vice President of Early Oncology Development at bluebird bio and Global Program and Clinical Development Leader for bluebird bio’s now FDA approved idecabtagene vicleucel (Ide-cel).

Travis held roles of increasing responsibility in Clinical Development at Foundation Medicine and Infinity Pharmaceuticals, demonstrating the utility of a pan-cancer genomic sequencing assay and anti-cancer small molecule natural compounds, respectively. Clinically, Travis worked at the Dana Farber Cancer Institute in Boston, with industry partners, on Phase 1 through registration clinical trials for Gleevec® and Sutent® for Gastrointestinal Stromal Tumors and Yondelis® in Soft Tissue Sarcomas, along with many other new molecular entities entering early development. 

bottom of page